You are here

Tetra Bio-Pharma Confirms Agreements With Multiple Suppliers

Quality and volume of Active Pharmaceutical Ingredients (API) ensured

ORLEANS, Ontario, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF) a leader in cannabinoid-based drug discovery and development confirms its non-exclusive supply agreement for GMP-Grade THC with U.S.-based Rhodes Technologies Inc. The supply will be used for several drug development activities including Tetra’s cannabinoid-derived products PPP002, PPP003, and PPP004, as well as for discovery phase projects.  This is additional to having a supply agreement with True North Cannabis Inc.  for CBD from hemp which was necessary to meeting the demand associated with the Genacol Corporation transaction.

With a robust development pipeline, it is essential for Tetra to have a reliable, API supply to support our expanding needs and avoid product shortages,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “Our agreement with Rhodes is predicated on their long history and expertise in the production and sale of active chemical ingredients, particularly in the area of pain management.  In terms of CBD, our suppliers are selected based on their ability to provide us with both quality (GMP Pharmaceutical Grade) and volume.  Tetra is always mindful of the need to have consistent supply as well as back-ups for each of the products under development.”

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard                                     
Executive Vice President, Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com       
  
Media Contact  
energi PR
 
Carol LevineStephanie Engel 
Carol.Levine@energipr.comstephanie.engel@energipr.com   
514-288-8500 ext. 226 416-425-9143 ext. 209 

 

Tuesday, December 11, 2018 - 06:30